相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immunotherapy in Bladder Cancer
Venu Madhav Konala et al.
AMERICAN JOURNAL OF THERAPEUTICS (2022)
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer
Ken Kato et al.
FUTURE ONCOLOGY (2019)
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
Yung-Jue Bang et al.
GASTRIC CANCER (2019)
Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-)181 study.
Takashi Kojima et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS)
A. Adenis et al.
EUROPEAN JOURNAL OF CANCER (2019)
Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors
Lizza E. L. Hendriks et al.
EUROPEAN JOURNAL OF CANCER (2019)
Esophageal and Esophagogastric Junction Cancers, Version 2.2019
Jaffer A. Ajani et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
Nicholas D. Klemen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato et al.
LANCET ONCOLOGY (2019)
Check point inhibitors a new era in renal cell carcinoma treatment
Mohamed Alsharedi et al.
MEDICAL ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Leisha A. Emens et al.
EUROPEAN JOURNAL OF CANCER (2017)
Systematic Review of Immune Checkpoint Inhibition in Urological Cancers
Maud Rijnders et al.
EUROPEAN UROLOGY (2017)
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer
Russell D. Petty et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Metronomic chemotherapy and immunotherapy in cancer treatment
Yu-Li Chen et al.
CANCER LETTERS (2017)
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
Shumei Kato et al.
CLINICAL CANCER RESEARCH (2017)
Global Cancer Incidence and Mortality Rates and Trends-An Update
Lindsey A. Torre et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2016)
Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Young Kwang Chae et al.
CLINICAL LUNG CANCER (2016)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
Xiangjiao Meng et al.
CANCER TREATMENT REVIEWS (2015)
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Scott N. Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Matias E. Valsecchi
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches
Qin Pan et al.
STEM CELLS (2015)
Combined immunotherapy improves survival in metastatic melanoma
S. Mayor
BMJ-British Medical Journal (2015)
Combined immunotherapy improves survival in metastatic melanoma
S. Mayor
BMJ-British Medical Journal (2015)
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Leisha A. Emens et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
Abhishek D. Garg et al.
FRONTIERS IN IMMUNOLOGY (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Immunotherapy: A useful strategy to help combat multidrug resistance
Tyler J. Curiel
DRUG RESISTANCE UPDATES (2012)
PHASE II STUDY OF CHEMORADIOTHERAPY WITH 5-FLUOROURACIL AND CISPLATIN FOR STAGE II-III ESOPHAGEAL SQUAMOUS CELL CARCINOMA: JCOG TRIAL (JCOG 9906)
Ken Kato et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy
C Blank et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
分享论文
